Pharma Acquisition Surge: FTC Greenlights Aurobindo's $250M Buyout of Generic Giant Lannett

Pharma Acquisition Surge: FTC Greenlights Aurobindo's $250M Buyout of Generic Giant Lannett​

Strategic Expansion in Controlled Substances Market​

Aurobindo Pharma has announced a significant strategic victory, confirming that its US subsidiary, Aurobindo Pharma USA, Inc., has received approval from the U.S. Federal Trade Commission (FTC). This crucial regulatory nod greenlights the acquisition of Lannett Company LLC for USD 250 million. The deal is set to close within the current month, according to a recent regulatory filing by Aurobindo Pharma.

Lannett, based in Pennsylvania, is a specialized generic pharmaceutical company. It focuses on developing and commercializing a diverse portfolio of complex, non-opioid controlled substances. The acquisition represents a major step forward for Aurobindo USA’s product line within this high-growth segment.

Bolstering Manufacturing and Product Portfolio​

The transaction holds dual benefits for the acquiring entity. Firstly, it significantly expands Aurobindo USA's existing product offering in the complex, non-opioid controlled substances space. Secondly, it immediately adds a specialized US-based manufacturing facility to Aurobindo’s operational network.

Swami S Iyer, CEO of Aurobindo Pharma USA, stated that this acquisition offers a "highly compelling strategic and financial opportunity." He added that it will accelerate revenue growth and significantly strengthen the company's presence in complex, non-opioid controlled substances within the US market.

Impact on Earnings and Supply Chain Resilience​

The acquisition is anticipated to be immediately accretive to Aurobindo Group’s earnings per share. Beyond financial gain, the merger promises to enhance the corporate portfolio with a differentiated pipeline of specialized generics and controlled substances. This development aims to support sustainable long-term growth for the integrated company.

Lannett's manufacturing facility located in Seymour, Indiana, provides substantial production capacity. The site is capable of scaling production up to approximately 4 billion doses annually. This enhanced domestic capability perfectly aligns with US policy initiatives focused on improving supply chain resilience and boosting domestic pharmaceutical output.

Commitment to Affordability and Accessibility​

The strategic importance extends beyond market share and manufacturing capacity. Tim Crew, CEO of Lannett Company, emphasized the role Aurobindo plays in patient access. He stated that "Aurobindo's market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere."

By absorbing a specialist firm like Lannett, Aurobindo is not only strengthening its domestic footprint but also reinforcing its commitment to affordable healthcare. The integration of Lannett’s expertise and infrastructure promises deeper penetration into the complex generics market, solidifying Aurobindo Pharma USA's role in the global pharmaceutical landscape.